drugset
drugset / Trial / NCT04638660

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660 ↗

Phase 3 Completed 144 enrolled Ocuphire Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are: * To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) * To evaluate efficacy of Nyxol to improve visual performance * To evaluate the safety of Nyxol

Timeline

Start
2020-12-30
Primary completion
2022-05-19
Completion
2022-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentolamine Small molecule 0.75 % Topical

Indications

vision disorder